Arcutis Biotherapeutics, Inc. ARQT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenue, net by Product | ||||||
| ZORYVE Cream0.15 | $79.8M+16.9% | $68.27M+33.2% | $51.25M+47.5% | $34.76M+72.6% | $20.14M+103% | |
| ZORYVE Cream0.3 | $130.28M+7.7% | $121M+7.7% | $112.31M+8.1% | $103.86M+11.1% | $93.44M+9.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arcutis Biotherapeutics, Inc. break its business down?
- Arcutis Biotherapeutics, Inc. (ARQT) reports product revenue, net by product across 3 parts — ZORYVE Cream0.05, ZORYVE Cream0.15 and ZORYVE Cream0.3. Each is extracted from the segment footnotes and tracked over time.
- Where does Arcutis Biotherapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arcutis Biotherapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.